FALLOPIAN TUBE CANCER

This study tests an experimental drug called IMGN151 for people with gynecologic cancers, including ovarian cancer. The drug is given alone or with other cancer treatments to see if it is safe and works. About 377 adults will take part at sites worldwide. The goal is to find bett…

This study tests whether adding a vitamin A-like drug (ATRA) to a platelet-boosting medication (romiplostim N01) works better than the platelet drug alone for cancer survivors whose platelet counts stay low after chemotherapy. About 220 adults with gynecologic, breast, or lung ca…

This study tests whether adding bevacizumab to niraparib after standard chemotherapy works better than niraparib alone for women with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer. About 970 participants will be randomly assigned to one of two treatment p…

This study tests a new drug called Rina-S in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 764 participants will receive th…

This study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better reduce cancer before surgery in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly as…

This study tests whether a cancer-killing virus (Olvi-Vec) given into the abdomen can make platinum-resistant ovarian cancer respond to chemotherapy again. About 186 women whose cancer has not responded to at least three prior treatments will receive either Olvi-Vec plus chemo an…

This study tests an experimental drug, REGN5668, alone or with other immune-boosting medicines in people with ovarian, fallopian tube, peritoneal, or endometrial cancers. The goal is to find the safest dose and see if the combination shrinks tumors. About 612 adults whose cancer …

This study tests a new drug combination (carboplatin plus mirvetuximab soravtansine) given before surgery to people with advanced ovarian, fallopian tube, or peritoneal cancer that has a specific protein (FRα). The goal is to see if the treatment shrinks tumors enough to improve …

This early-phase study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. The main goals are to find safe doses and ch…

This study tests if removing lymph nodes near the liver (hepato-celiac lymphadenectomy) can help control advanced or recurrent ovarian cancer. About 94 women with stage III/IV or platinum-sensitive recurrent ovarian cancer will have this surgery. The main goal is to see how many …

This study tests whether adding a targeted drug (olaparib) to heated chemotherapy during surgery can safely treat advanced ovarian cancer. About 55 adults with stage III ovarian cancer will receive the drug before and during surgery. The goal is to find the best dose and check fo…

This study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…

This study tests an experimental drug called ART0380 in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with other chemotherapy drugs like gemcitabine or irinotecan. About 442 participants wi…

This study tests whether a new drug combination (sacituzumab tirumotecan with or without bevacizumab) can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 adults who have already had two rounds of chemotherapy will…

This study tests an experimental drug called ubamatamab, alone or with other cancer drugs, in people with advanced ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see how safe and effective these combinations are. About 220 participants w…

This study tests whether combining two drugs, senaparib and temozolomide, can shrink tumors in people with a certain type of ovarian cancer linked to an ARID1A gene change. About 18 adults with recurrent or persistent clear cell or endometrioid ovarian, fallopian tube, or primary…

This study is for women with advanced ovarian cancer that has been fully removed by surgery. It compares 3 cycles of chemotherapy followed by the maintenance drug niraparib against the standard 6 cycles plus niraparib. The goal is to see if the shorter chemo course works just as …

This study tests a technique called acute normovolemic hemodilution (ANH) during ovarian cancer surgery. Before surgery, some blood is removed and replaced with fluids, then returned later. The goal is to see if this reduces the need for donor blood transfusions. About 86 adults …

This early-phase study tests a new drug called XMT-1660 in people with advanced solid tumors, including triple-negative breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. About 319 participants will receive the drug to…

This study is testing whether a combination of two drugs, mirvetuximab soravtansine and olaparib, can help keep recurrent ovarian, peritoneal, or fallopian tube cancer from growing back after initial treatment. The trial involves 53 women whose cancer has returned but still respo…

This phase 3 trial tests whether adding the experimental drug IMNN-001 to standard chemotherapy improves survival in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. About 500 newly diagnosed participants will receive either the combination or chemother…

This study tests a drug called TORL-1-23 in 230 women with advanced ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum chemotherapy and has a specific marker (claudin 6). The goal is to see if the drug can shrink tumors and how safe it is. Participa…

This study tests a drug called relacorilant combined with other treatments for people with ovarian, fallopian tube, peritoneal, or endometrial cancers. About 270 participants will join to see if the combination helps slow cancer growth. The goal is to control the disease, not cur…

This early-phase study tests an experimental treatment called 27T51, a type of CAR T cell therapy that targets a protein (MUC16) found on certain cancer cells. It is for women with recurrent or hard-to-treat ovarian, peritoneal, or fallopian tube cancer. The study has two parts: …

This study tests whether adding mirvetuximab soravtansine to standard maintenance therapy (bevacizumab) can delay cancer regrowth in people with a specific type of ovarian, fallopian tube, or peritoneal cancer. Participants must have cancer that responded to initial platinum-base…

This early-phase study tests a new two-drug combination (Cirtuvivint and Olaparib) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy. About 50 participants will take the pills at different schedules to find the safest do…

This phase 3 trial tests whether the experimental drug BL-B01D1 works better than standard chemotherapy for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatment. About 384 adults who have had 1-3 prior treatment…

This study looks at whether removing the fallopian tubes first and delaying ovary removal is as safe as removing both at once for preventing ovarian cancer in women with BRCA or other high-risk gene mutations. About 100 premenopausal women aged 25-50 will choose their preferred s…

This early-phase study is testing whether adding aspirin to standard chemotherapy can reduce immune-suppressing cells inside ovarian, fallopian tube, or peritoneal tumors. About 100 women will take aspirin alongside their chemo before surgery. The goal is to see if this simple, l…

This study looks at how the antifungal drug itraconazole changes the levels of a cancer drug in the blood of people with ovarian, primary peritoneal, or fallopian tube cancer. About 24 participants will take both drugs in a fixed order to measure drug levels over time. The goal i…

This study follows 1,000 women newly diagnosed with ovarian, fallopian tube, or primary peritoneal cancer to see how their genes (BRCA and HRD) affect their response to standard chemotherapy and surgery. Researchers will track treatment outcomes, including how much cancer is remo…